New combo therapy offers hope for patients with returning lymphoma
Disease control
Recruiting now
This study tests a new drug, epcoritamab, combined with standard chemotherapy (GDP) in 32 adults whose large B-cell lymphoma has returned or not responded to treatment. The goal is to see if this combination can shrink or eliminate the cancer. After three cycles, patients may pro…
Phase: PHASE2 • Sponsor: Dipenkumar Modi • Aim: Disease control
Last updated May 08, 2026 12:02 UTC